Zobrazeno 1 - 10 of 716 pro vyhledávání: '"Leiter La"'
1
Akademický článek
Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
Autor: Lachaine J, Charron JN, Gregoire JC, Hegele RA, Leiter LA
Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 295-308 (2023)
Jean Lachaine,1,2 Jean-Nicolas Charron,2 Jean C Gregoire,3 Robert A Hegele,4 Lawrence A Leiter5 1University of Montreal, Montreal, QC, Canada; 2PeriPharm Inc., Montreal, QC, Canada; 3Institut de cardiologie de Montréal, Montreal, QC, Canada; 4Robart
Externí odkaz: https://doaj.org/article/6742bb7185f545988a542d69ec56e146
Zobrazit plný text záznamu
2
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Autor: Bhatt, Dl, Szarek, M, Pitt, B, Cannon, Cp, Leiter, La, Mcguire, Dk, Lewis, Jb, Riddle, Mc, Inzucchi, Se, Kosiborod, Mn, Cherney, Dzi, Dwyer, Jp, Scirica, Bm, Bailey, Cj, Díaz, R, Ray, Kk, Udell, Ja, Lopes, Rd, Lapuerta, P, Steg, Gabriel, P, Lauro, D
Publikováno v: Bhatt, D L, Szarek, M, Pitt, B, Cannon, C P, Leiter, L A, McGuire, D K, Lewis, J B, Riddle, M C, Inzucchi, S E, Kosiborod, M N, Cherney, D Z I, Dwyer, J P, Scirica, B M, Bailey, C J, Díaz, R, Ray, K K, Udell, J A, Lopes, R D, Lapuerta, P, Steg, P G & SCORED Investigators 2021, ' Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ', The New England Journal of Medicine, vol. 384, no. 2, pp. 129-139 . https://doi.org/10.1056/NEJMoa2030186
NEW ENGLAND JOURNAL OF MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, my
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9705eeadc025b1e0478507d16cdaa4
https://pure.au.dk/portal/da/publications/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease(6bc50c6b-8a7a-4eea-bd9e-9032680e8b64).html
Zobrazit plný text záznamu
3
Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1
Autor: Landmesser, U, Haghikia, A, Leiter, LA, Wright, RS, Kallend, D, Wijngaard, P, Stoekenbroek, R, Kastelein, JJP, Ray, KK
INTRODUCTION: siRNA-based targeting of PCSK9 represents a novel therapeutic approach that may provide a convenient, infrequent and safe dosing schedule to robustly lower LDL-C. Given the long duration of action, however, establishing safety in partic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::a1871284f9cf60ccf2ac215121c1b7bd
http://hdl.handle.net/10044/1/78216
Zobrazit plný text záznamu
7
Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke
Autor: Verma, S, Poulter, NR, Bhatt, DL, Bain, SC, Buse, JB, Leiter, LA, Nauck, MA, Pratley, RE, Zinman, B, Ørsted, DD, Monk Fries, T, Rasmussen, S, Marso, SP
BACKGROUND: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes). In a post hoc analysis,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::764ce016788f74baa45c3769fb06c58f
http://hdl.handle.net/10044/1/90481
Zobrazit plný text záznamu
8
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial
Autor: Verma, S, Bhatt, DL, Bain, SC, Buse, JB, Mann, JFE, Marso, SP, Nauck, MA, Poulter, NR, Pratley, RE, Zinman, B, Michelsen, MM, Monk Fries, T, Rasmussen, S, Leiter, LA, LEADER Publication Committee on behalf of the LEADER Trial Investigators
Publikováno v: Circulation. 137(20)
The presence of polyvascular disease, defined as atherosclerosis involving >1 distinct vascular territory, is a strong, independent predictor of cardiovascular events.1–4 In the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e2c5dacf1c7dd3a3d9c86963213246a
https://pubmed.ncbi.nlm.nih.gov/29760228
Zobrazit plný text záznamu
9
Inflammatory and cholesterol risk in the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in patients with elevated risk)
Autor: Bohula, EA, Giugliano, RP, Leiter, LA, Verma, S, Park, J-G, Sever, PS, Pineda, AL, Honarpour, N, Wang, H, Murphy, SA, Keech, A, Pedersen, TR, Sabatine, MS
BACKGROUND : In the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein choleste
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::0bb3145cfc6b742d61f8d2953fbfc831
http://hdl.handle.net/10044/1/57925
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje